Open Access<p>Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD</p>
Author(s) -
Masakazu Ichinose,
Yasushi Fukushima,
Yoshikazu Inoue,
Osamu Hataji,
Gary T. Ferguson,
Klaus F. Rabe,
Nobuya Hayashi,
Hiroshi Okada,
Mami Takikawa,
Eric Bourne,
Shaila Ballal,
Kiernan DeAngelis,
Magnus Aurivillius,
Colin Reisner,
Paul Dorinsky
Publication year - 2019
Publication title -
international journal of chronic obstructive pulmonary disease/international journal of copd
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.394
H-Index - 67
eISSN - 1178-2005
pISSN - 1176-9106
DOI - 10.2147/copd.s220861
Subject(s) - medicine , formoterol fumarate , glycopyrrolate , budesonide , metered dose inhaler , inhaler , copd , formoterol , anesthesia , asthma , inhalation , atropine
Budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler (BGF MDI) is a triple fixed-dose combination for COPD. The long-term safety of triple therapy for COPD has not been investigated in Japanese patients. In this 28-week extension study (NCT03262012), we investigated the long-term safety and tolerability of BGF MDI in Japanese patients with moderate-to-very severe COPD who completed the 24-week Phase III randomized, double-blind, multicenter KRONOS study (NCT02497001).